Free Trial
NASDAQ:ACTU

Actuate Therapeutics (ACTU) Stock Price, News & Analysis

Actuate Therapeutics logo
$6.75 -0.30 (-4.26%)
Closing price 04:00 PM Eastern
Extended Trading
$6.72 -0.03 (-0.37%)
As of 05:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Actuate Therapeutics Stock (NASDAQ:ACTU)

Key Stats

Today's Range
$6.65
$7.29
50-Day Range
$7.05
$11.36
52-Week Range
$5.51
$11.99
Volume
96,960 shs
Average Volume
51,900 shs
Market Capitalization
$132.44 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$20.50
Consensus Rating
Buy

Company Overview

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.

Actuate Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
27th Percentile Overall Score

ACTU MarketRank™: 

Actuate Therapeutics scored higher than 27% of companies evaluated by MarketBeat, and ranked 783rd out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Actuate Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Actuate Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Actuate Therapeutics' stock forecast and price target.
  • Price to Book Value per Share Ratio

    Actuate Therapeutics has a P/B Ratio of 675.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for ACTU.
  • Dividend Yield

    Actuate Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Actuate Therapeutics does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for ACTU.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Actuate Therapeutics this week, compared to 1 article on an average week.
  • Search Interest

    Only 2 people have searched for ACTU on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Actuate Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Actuate Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    69.34% of the stock of Actuate Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Read more about Actuate Therapeutics' insider trading history.
Receive ACTU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Actuate Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ACTU Stock News Headlines

A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
See More Headlines

ACTU Stock Analysis - Frequently Asked Questions

Actuate Therapeutics' stock was trading at $7.96 at the beginning of 2025. Since then, ACTU stock has decreased by 15.2% and is now trading at $6.75.
View the best growth stocks for 2025 here
.

Actuate Therapeutics, Inc. (NASDAQ:ACTU) issued its earnings results on Thursday, May, 15th. The company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.26) by $0.06.

Actuate Therapeutics (ACTU) raised $27 million in an IPO on Tuesday, August 13th 2024. The company issued 3,000,000 shares at a price of $8.00-$10.00 per share. Titan Partners served as the underwriter for the IPO and Newbridge Securities Corp. was co-manager.

Top institutional investors of Actuate Therapeutics include Voss Capital LP (0.73%), Sigma Planning Corp (0.12%), Goldman Sachs Group Inc. (0.11%) and Sfmg LLC (0.06%). Insiders that own company stock include Equity Cof Lp Bios, Todd S Thomson and Leslie W Kreis.
View institutional ownership trends
.

Shares of ACTU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Actuate Therapeutics investors own include Arch Capital Group (ACGL), Adobe (ADBE), Analog Devices (ADI), Alnylam Pharmaceuticals (ALNY), Aileron Therapeutics (ALRN), Amgen (AMGN) and AstraZeneca (AZN).

Company Calendar

Last Earnings
5/15/2025
Today
6/24/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ACTU
Previous Symbol
NASDAQ:ACTU
Web
N/A
Fax
N/A
Employees
10
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$20.50
High Stock Price Target
$21.00
Low Stock Price Target
$20.00
Potential Upside/Downside
+203.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$27.28 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$0.01 per share
Price / Book
675.00

Miscellaneous

Free Float
6,015,000
Market Cap
$132.44 million
Optionable
N/A
Beta
N/A
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

This page (NASDAQ:ACTU) was last updated on 6/24/2025 by MarketBeat.com Staff
From Our Partners